Compare FPH & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FPH | AURA |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.2M | 419.5M |
| IPO Year | 2013 | 2021 |
| Metric | FPH | AURA |
|---|---|---|
| Price | $5.22 | $7.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 176.7K | ★ 278.5K |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $110,020,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.40 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.72 | $4.73 |
| 52 Week High | $6.64 | $7.48 |
| Indicator | FPH | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 58.85 | 71.58 |
| Support Level | $4.95 | $5.94 |
| Resistance Level | $5.70 | $7.44 |
| Average True Range (ATR) | 0.19 | 0.32 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 86.20 | 89.11 |
Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational, and recreational elements, as well as civic areas, parks, and open spaces. Its four reportable segments are Valencia, San Francisco, Great Park, and Hearthstone. It derives the majority of revenue from the Great Park segment, which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.